FDA Approves Gore's TAG Conformable Thoracic Stent Graft With Active Control

 

May 15, 2019—Gore & Associates announced that the FDA has approved the company's TAG conformable thoracic stent graft with Active Control system for thoracic endovascular aortic repair. The device and delivery system provide precision and predictable patient outcomes in the endovascular repair of aneurysms, transections, and type B dissections of the descending thoracic aorta. A smaller-diameter primary delivery sleeve gives the device and system a lower profile across 10 device sizes.

According to Gore, the Active Control system provides controlled, two-stage deployment with primary deployment to an intermediate diameter and a secondary deployment to full diameter. This design allows for continuous blood flow throughout the deployment with multiple opportunities to visualize and refine graft placement. It is also designed to allow for angulation of the proximal end of the device for improved seal and apposition.

Gore advised that no change was made to the stent graft itself, which has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions). Large device oversizing windows were engineered, tested, and proven to accommodate differences in proximal and distal landing zone diameters: a 6% to 33% oversizing window allows physicians to choose the optimal radial force to fit patient anatomy and etiology. The 16- to 42-mm range can be treated with as few as five sizes, allowing providers to stock fewer devices while treating a broader range of patients, stated the company.

The TAG conformable thoracic stent graft with Active Control system was approved for use in Europe in July 2017 and in Australia in July 2018.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.